Bioluminescence Imaging of an Immunocompetent Mouse Model for Glioblastoma
JoVE Encyclopedia of Experiments
Neuroscience
0 views • 2:28 min • June 17th, 2025
Loading...
Overview
This article describes a method for imaging glioblastoma growth in an immunocompetent mouse model using bioluminescence. The technique involves the use of luciferase-expressing tumor cells and luciferin to visualize tumor proliferation over time.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Imaging Techniques
Background
- Glioblastoma is a highly aggressive brain tumor.
- Imaging techniques are essential for monitoring tumor growth.
- Bioluminescence imaging allows for real-time visualization of tumor dynamics.
- Luciferase and luciferin provide a non-invasive method to assess tumor burden.
Purpose of Study
- To establish a reliable method for monitoring glioblastoma growth in vivo.
- To utilize bioluminescence imaging for quantifying tumor cell proliferation.
- To assess the effectiveness of imaging parameters in capturing tumor dynamics.
Methods Used
- Implantation of luciferase-expressing tumor cells in the brain of anesthetized mice.
- Administration of luciferin to visualize tumor cells.
- Use of a bioluminescence imaging system to capture luminescent signals.
- Quantification of bioluminescent signals over time to assess tumor growth.
Main Results
- Successful imaging of glioblastoma growth was achieved.
- Increased luminescence signals correlated with tumor cell proliferation.
- Imaging parameters were optimized for accurate signal acquisition.
- Monitoring over several days provided insights into tumor dynamics.
Conclusions
- The bioluminescence imaging method is effective for monitoring glioblastoma growth.
- This technique can be used to evaluate therapeutic interventions.
- Further studies can enhance understanding of tumor biology in vivo.
Frequently Asked Questions
What is the significance of using luciferase in tumor imaging?
Luciferase allows for non-invasive visualization of tumor cells through bioluminescence, providing real-time insights into tumor growth.
How does luciferin contribute to the imaging process?
Luciferin is a substrate that interacts with luciferase, producing a bioluminescent signal that can be quantified to assess tumor burden.
What are the advantages of bioluminescence imaging over other imaging techniques?
Bioluminescence imaging is non-invasive, allows for real-time monitoring, and provides high sensitivity for detecting tumor growth.
Can this method be applied to other types of tumors?
Yes, the bioluminescence imaging technique can be adapted for various tumor types that express luciferase.
What are the limitations of this imaging technique?
Limitations include the requirement for luciferase expression and potential variability in luciferin distribution among different tissues.
How can this study impact future cancer research?
This study provides a framework for using bioluminescence imaging to evaluate tumor growth and treatment responses in preclinical models.
Executive Industry Relevance
Bioluminescence imaging enables non-invasive, longitudinal tracking of tumor burden in immunocompetent models, supporting early-stage target validation and therapeutic hypothesis testing in neuro-oncology. This approach provides quantitative, reproducible readouts that enhance predictive confidence in preclinical glioblastoma studies and inform go/no-go decisions prior to lead optimization.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying tumor proliferation in an immunocompetent microenvironment.
- Operational Value: Supports biological de-risking through real-time, non-invasive monitoring of glioblastoma growth dynamics.
- Predictive Value: Facilitates portfolio triage by correlating luminescence signals with tumor cell count for objective efficacy assessment.
Screening & Assay Development
- Assay Readiness: Prepares validated luciferase-expressing tumor models for downstream compound screening with standardized imaging parameters.
- Quantitative Output: Generates photons per second per steradian per square centimeter measurements enabling reliable compound evaluation.
- Scalability: Supports platform reuse across studies through consistent signal acquisition and region-of-interest analysis workflows.
Translational & Preclinical Research
- Disease Relevance: Models human glioblastoma progression in an immunocompetent system, enhancing translational biomarker alignment.
- Preclinical Continuity: Bridges discovery to preclinical validation by providing longitudinal tumor growth data for risk-adjusted advancement decisions.
- Mechanistic De-risking: Reduces ambiguity in target validation by linking luciferase signal changes to therapeutic intervention outcomes.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target validation through lead identification to preclinical efficacy testing, enabling iterative assessment of therapeutic candidates in a disease-relevant system.
- Discovery Biology: Supports hypothesis testing and pathway clarification by monitoring tumor proliferation in response to genetic or pharmacological modulation.
- Screening: Ensures assay readiness through reproducible bioluminescence signal quantification across time points and experimental groups.
- Analytics: Delivers quantitative luminescence measurements that allow teams to compare tumor burden conditions and calculate growth rates.
- Translational Research: Connects to preclinical continuity by providing longitudinal data that informs dose-response and therapeutic window assessments.
- Enterprise Reuse: Establishes a reusable imaging platform for neuro-oncology projects requiring longitudinal tumor tracking in immunocompetent models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity through direct tumor burden quantification.
- Operational Value: Enhances standardization and reproducibility via defined imaging protocols and signal quantification procedures.
- Strategic Value: Improves go/no-go decision-making by providing objective, longitudinal efficacy data that reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on quantifiable tumor growth inhibition in a physiologically relevant model.
Implementation Considerations
- Requires expertise in intracranial tumor implantation and bioluminescence imaging system operation.
- Dependent on access to luciferase-expressing cell lines and luciferin substrate for signal generation.
- Necessitates standardized anesthesia and animal handling procedures to ensure consistent signal acquisition.
- Involves cross-team alignment on region-of-interest definition and photon measurement protocols for data comparability.
- Limited to models where luciferase expression is stable and luciferin bioavailability is sufficient for detectable signal.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in bioluminescence imaging?
Null hypothesis testing determines whether observed changes in bioluminescent signal are statistically significant, supporting objective evaluation of therapeutic effects on tumor growth in immunocompetent models.
How does independent variable isolation fit the discovery pipeline in this imaging method?
Isolating independent variables such as drug dosage or genetic modification allows researchers to attribute changes in luminescence signal specifically to the intervention, strengthening causal inference in target validation.
What quantitative dependent variable measurements enable tumor growth assessment?
Dependent variable measurements of photons per second per steradian per square centimeter quantify bioluminescent signal intensity, which correlates with luciferase-expressing tumor cell number over time.
Why do replication requirements matter for cross-functional collaboration in this workflow?
Replication ensures that bioluminescence imaging results are consistent across experiments and operators, enabling reliable data sharing between discovery, preclinical, and translational teams for unified decision-making.
What statistical analysis capabilities are required before implementing this imaging method?
Implementation requires capability to perform longitudinal signal comparison, growth rate calculation, and significance testing (e.g., t-tests or ANOVA) to determine whether observed tumor changes exceed experimental variability.
08:05
Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Related Videos
0 Views
09:32
Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils
Related Videos
0 Views
06:12
Intracerebral Transplantation and In Vivo Bioluminescence Tracking of Human Neural Progenitor Cells in the Mouse Brain
Related Videos
0 Views
11:09
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Related Videos
0 Views
11:02
In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model
Related Videos
0 Views
09:46
Intracranial Implantation with Subsequent 3D In Vivo Bioluminescent Imaging of Murine Gliomas
Related Videos
0 Views
10:52
Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme
Related Videos
0 Views
02:27
Bioluminescence Imaging in an EAE Mouse Model
Related Videos
0 Views
02:08
Bioluminescence Imaging to Assess Tumor Growth in an Organotypic Mouse Brain Slice
Related Videos
0 Views
09:52
An Orthotopic Glioblastoma Mouse Model Maintaining Brain Parenchymal Physical Constraints and Suitable for Intravital Two-photon Microscopy
Related Videos
0 Views
Last updated: 1 August 2026